Recent Finacing
Recent Raise
iECURE develops mutation-agnostic in vivo gene-insertion therapies for liver disorders, using AAV-delivered endonuclease and donor vectors (ARCUS licensed) to integrate full genes, collaborating with UPenn on preclinical-to-IND programs.
